The global nanotechnology drug delivery market is expected to reach USD 167.47 billion by 2030, growing at a CAGR of 8.9% from 2023 to 20230. The market is driven by the increasing demand for targeted therapies, advancements in nanomaterials, and collaborations between pharmaceutical companies and nanotechnology firms. However, regulatory challenges, cost barriers, and safety concerns pose obstacles for market players.
The report highlights key trends, including nanoparticle-based therapeutics, personalized medicine, and nanoformulations for cancer treatment. It also covers emerging areas such as biodegradable nanomaterials, intranasal drug delivery, and disease-specific treatments. The market is segmented by technology (nanocrystals, nanoparticles, liposomes, micelles, and others), application (neurology, oncology, cardiovascular, and others), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).
The report provides insights into the competitive landscape, including top companies such as Merck, Bayer, Amgen, Pfizer, and Novartis. It also addresses challenges, opportunities, and outlook for the market. The report is a comprehensive analysis of the Nanotechnology Drug Delivery Market, offering valuable insights for businesses, investors, and researchers.